Physician profile
Hernan R Baquerizo
NPI 1053378893
$17,244.70
in general payments reported to CMS, 2019-2025
43 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,942 · 2020: $2,661 · 2021: $3,200 · 2022: $2,720 · 2023: $2,241 · 2024: $1,666 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,721.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,181.80 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Astrazeneca Pharmaceuticals LP | $1,986.45 | 2019-2023 | Farxiga, Lokelma |
| Mannkind Corporation | $1,800.30 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $1,662.84 | 2019-2024 | |
| Novo Nordisk INC | $1,264.68 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,117.48 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amneal Pharmaceuticals LLC | $1,104.67 | 2019-2025 | Unithroid |
| Abbvie INC. | $807.79 | 2019-2025 | Synthroid |
| Abbott Laboratories | $656.88 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $420.35 | 2020-2025 | Gvoke Hypopen |
| Amgen INC. | $405.09 | 2019-2025 | Tepezza, Evenity, Prolia |
| Cequr Corporation | $333.82 | 2022-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $297.07 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $285.78 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $266.78 | 2019-2023 | Steglujan, Steglatro |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $263.46 | 2019-2020 | |
| Corcept Therapeutics | $261.21 | 2023-2025 | Korlym |
| Radius Health, INC. | $255.34 | 2019-2025 | |
| Insulet Corporation | $243.06 | 2019-2025 | Omnipod |
| Zealand Pharma US, INC. | $225.05 | 2020-2021 | |
| Esperion Therapeutics, INC. | $214.23 | 2020-2025 | Nexletol |
| Shire North American Group INC | $160.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.31 | 2021-2025 | |
| Medtronic, INC. | $117.21 | 2021-2023 | Minimed 780g |
| Amarin Pharma, INC. | $107.73 | 2019-2021 | |
| Lifescan, INC. | $107.14 | 2020-2022 | |
| Horizon Therapeutics Plc | $90.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $49.37 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $45.59 | 2025 | Yorvipath |
| Ibsa Pharma INC. | $36.28 | 2019-2022 | |
| Senseonics, Incorporated | $36.00 | 2020 | |
| Beta Bionics, INC. | $31.80 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $26.87 | 2024 | Crysvita |
| Neurocrine Biosciences, INC. | $26.74 | 2025 | |
| Madrigal Pharmaceuticals | $26.31 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $25.45 | 2025 | Arexvy, Shingrix |
| Pfizer INC. | $24.64 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $23.64 | 2025 | Imcivree |
| Sequel Med Tech, LLC | $23.54 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $21.95 | 2021 | |
| Antares Pharma, INC. | $21.95 | 2021 | |
| Clarus Therapeutics INC. | $19.79 | 2021 | |
| Currax Pharmaceuticals LLC | $16.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernan Baquerizo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.